Atlanta, Georgia–(Newsfile Corp. – January 25, 2021) – Holzer & Holzer, LLC is investigating whether Neoleukin Therapeutics, Inc. (NASDAQ: NLTX) (“Neoleukin” or the “Company”) complied with federal securities laws. On January 8, 2021, Neoleukin announced that “on January 7, 2021, it received a clinical hold letter from the U.S. Food and Drug Administration (FDA) related to its Investigational New Drug (IND) Application to begin a Phase 1 clinical program of its immunotherapeutic candidate, NL-201.” The price of Neoleukin’s stock fell following the announcement.
If you purchased shares of Neoleukin and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at [email protected] or Luke R. Kennedy, Esq. at [email protected], or by toll-free telephone at (888) 508-6832 to discuss your legal rights or at www.holzerlaw.com.
Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey D. Holzer is the attorney responsible for its content.
CONTACT:
Corey D. Holzer, Esq.
(888) 508-6832 (toll-free)
[email protected]
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/72766